Login to Your Account



Agency Admits Mistake

FDA Ends Orphan Exclusivity For Octapharma Drug Wilate

By Mari Serebrov
Washington Editor

Friday, August 10, 2012
In an agency first, the FDA is rescinding an orphan drug exclusivity, saying it made a mistake two years ago in determining that Octapharma USA Inc.'s Wilate was superior to CSL Behring LLC's previously approved Humate-P.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription